Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Mutations in oncogenes and tumor suppressor genes are responsible for tumorigenesis and represent favored therapeutic targets in oncology. We exploited homologous recombination to knock-in individual cancer mutations in the genome of nontransformed human cells. Sequential introduction of multiple mutations was also achieved, demonstrating the potential of this strategy to construct tumor progression models. Knock-in cells displayed allele-specific activation of signaling pathways and mutation-specific phenotypes different from those obtainable by ectopic oncogene expression. Profiling of a library of pharmacological agents on the mutated cells showed striking sensitivity or resistance phenotypes to pathway-targeted drugs, often matching those of tumor cells carrying equivalent cancer mutations. Thus, knock-in of single or multiple cancer alleles provides a pharmacogenomic platform for the rational design of targeted therapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Mutant PIK3CA promotes cell growth and invasion of human cancer cells.
Samuels, Y., Diaz, L. A., Schmidt-Kittler, O., Cummins, J. M., DeLong, L., Cheong, I., Rago, C., Huso, D. L., Lengauer, C., Kinzler, K. W., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.05.014 · Cited by 915
Benvenuti, S., Sartore-Bianchi, A., Di Nicolantonio, F., Zanon, C., Moroni, M., Veronese, S., Siena, S., & Bardelli, A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4158 · Cited by 830 · cited 1×
“We and others have previously shown that constitutive activation of the RAS/RAF pathway (for example by oncogenic KRAS mutations) can impair the response to drugs targeting EGFR (24, 25).”
BackgroundSelf-citationTuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Carey, K. D., Garton, A. J., Romero, M. S., Kahler, J., Thomson, S., Ross, S., Park, F., Haley, J. D., Gibson, N., & Sliwkowski, M. X. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0453 · Cited by 445
Research works printed but not linked: 31
- 10.1158/0008-5472.CAN-07-1126 · DOI · Paper page
- 10.1016/S1535-6108(03)00191-0 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-0108 · DOI · Paper page
- 10.1038/5056 · DOI · Paper page
- JW Shay, WE Wright, D Brasiskyte, BA Van der Haegen, E6 of human papillomavirus type 16 can overcome the M1 stage of immortalization in human mammary epithelial cells but not in human fibroblasts. Oncogene 8, 1407–1413 (1993).
- 10.1016/S1046-2023(03)00032-X · DOI · Paper page
- 10.1158/0008-5472.CAN-05-2612 · DOI · Paper page
- 10.1038/sj.onc.1209640 · DOI
- 10.1200/JCO.2005.07.799 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-3752 · DOI · Paper page
- 10.1158/0008-5472.CAN-05-2521 · DOI · Paper page
- 10.1089/dna.2006.0573 · DOI · Paper page
- 10.1158/0008-5472.CAN-06-3339 · DOI · Paper page
- 10.1038/sj.onc.1210503 · DOI
- 10.1158/0008-5472.CAN-07-0217 · DOI · Paper page
- 10.1016/j.ccr.2007.06.013 · DOI · Paper page
- 10.1186/1471-2105-8-3 · DOI · Paper page
- 10.1016/S0021-9258(18)45614-1 · DOI · Paper page
- 10.1126/science.1101637 · DOI · Paper page
- 10.1371/journal.pmed.0020017 · DOI · Paper page
- KG Higinbotham, JM Rice, GS Buzard, AO Perantoni, Activation of the K-ras gene by insertion mutations in chemically induced rat renal mesenchymal tumors. Oncogene 9, 2455–2459 (1994).
- 10.1074/jbc.271.51.32491 · DOI · Paper page
- 10.1056/NEJMoa040938 · DOI · Paper page
- 10.1126/science.1099314 · DOI · Paper page
- 10.1158/0008-5472.CAN-07-5084 · DOI · Paper page
- 10.1158/1078-0432.CCR-06-1992 · DOI
- 10.1073/pnas.94.18.9614 · DOI
- 10.1158/0008-5472.CAN-04-1911 · DOI · Paper page
- 10.1038/nature00766 · DOI · Paper page
- 10.1016/j.mrrev.2007.07.001 · DOI
- 10.1073/pnas.0703205104 · DOI
Cited by
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
Misale, S., Yaeger, R., Hobor, S., Scala, E., Janakiraman, M., Liska, D., Valtorta, E., Schiavo, R., Buscarino, M., Siravegna, G., et al. (2012) · Nature · doi:10.1038/nature11156 · Cited by 1,889
“Emergence of KRAS mutations and acquired resistance to anti EGFR therapy in colorectal cancer / Misale, S; Yaeger, R; Hobor, S; Scala, E; Janakiraman, M; Liska, D; Valtorta, E; Schiavo, R; Buscarino, M; Siravegna, G; Bencardino, K; Cercek, A; Chen, Ct; Veronese, S; Zanon, C; Sartore-Bianchi, A; Gambacorta, M; Gallicch…”
BackgroundSelf-citationMolecular Mechanisms of Resistance to Cetuximab and Panitumumab in Colorectal Cancer
Bardelli, A., & Siena, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.6116 · Cited by 746
Self-citationDe Roock, W., Jonker, D. J., Di Nicolantonio, F., Sartore-Bianchi, A., Tu, D., Siena, S., Lamba, S., Arena, S., Frattini, M., Piessevaux, H., et al. (2010) · JAMA · doi:10.1001/jama.2010.1535 · Cited by 748
Self-citationEGFR Blockade Reverts Resistance to KRASG12C Inhibition in Colorectal Cancer.
Amodio, V., Yaeger, R., Arcella, P., Cancelliere, C., Lamba, S., Lorenzato, A., Arena, S., Montone, M., Mussolin, B., Bian, Y., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0187 · Cited by 504
“To further assess the role of EGFR signaling in AMG510 resistance, we used the KRAS wild-type, cetuximab-sensitive colorectal cancer cell line LIM1215 to generate isogenic models carrying the KRASG12C allele using an AAV-mediated knock-in approach (21).”
MethodSelf-citationPrinciples for the post-GWAS functional characterization of cancer risk loci
Freedman, M. L., Monteiro, A. N. A., Gayther, S. A., Coetzee, G. A., Risch, A., Plass, C., Casey, G., De Biasi, M., Carlson, C., Duggan, D., et al. (2011) · Nature Genetics · doi:10.1038/ng.840 · Cited by 438
Metadata
- Authors
- Di Nicolantonio, F., Arena, S., Gallicchio, M., Zecchin, D., Martini, M., Flonta, S. E., Stella, G. M., Lamba, S., Cancelliere, C., Russo, M., Geuna, M., Appendino, G., Fantozzi, R., Medico, E., & Bardelli, A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2008-12-30
- Volume
- 105
- Issue
- 52
- Pages
- 20864-20869
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2164515926
- Cited by
- 92
- References
- 5
- FWCI
- 1.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. https://app.cochat.ai/papers/10.1073/pnas.0808757105
- The paper
- Di Nicolantonio, F., Arena, S., Gallicchio, M., Zecchin, D., Martini, M., Flonta, S. E., Stella, G. M., Lamba, S., Cancelliere, C., Russo, M., Geuna, M., Appendino, G., Fantozzi, R., Medico, E., & Bardelli, A. (2008). Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0808757105
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.